Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:22:06.571Z.
Consensus retrieved: 2026-10-06T12:16:26.573Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:22:06.571Z.
Quote observation: 2026-10-06T14:18:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48e811c8653d9a36ed2358e044162b897bef7919ece4b1f287edb0560ff82069
Forward PE Ratio (N/A) = Dated Quote Price ($8.56) / Consensus Forward EPS ($-0.38)
FORWARD PE RATIO
N/A
Harvard Bioscience, Inc.
Market Cap
$38.61M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Harvard Bioscience, Inc. (HBIO) | $38.61M | N/A |
| Incannex Healthcare Limited (IXHL)vs › | $38.96M | N/A |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | N/A |
| Edesa Biotech, Inc. (EDSA)vs › | $37.73M | N/A |
| Accuray Incorporated (ARAY)vs › | $36.59M | N/A |
| DocGo Inc. (DCGO)vs › | $36.38M | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $42.02M | N/A |
| CVRx, Inc. (CVRX)vs › | $42.46M | N/A |
| Elutia Inc (ELUT)vs › | $35.82M | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.75M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $8.56, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.38 | $-0.38 – $-0.38 | 1 | n/m |
| 2027-12-31 | $0.65 | $0.37 – $0.92 | 2 | 13.3x |
| 2028-12-31 | $0.00 | $0.00 – $0.00 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
